Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: Cross-over designed study

Neuroendocrinology Letters

Volumn 27, Issue 5, 2006, Pages 665-668

  Fait, Thomas ^a   Vrablik, Michal ^a   Cibula, David ^a   Masata, Jaromir ^a   Hill, Martin ^b   Trnkova, Bohuslava ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

D dimers; Estrogen replacement therapy; TFPI; Thromboembolism

Indexed keywords

ANGIOTENSIN III; D DIMER; ESTRADIOL; ESTROGEN; FIBRINOGEN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HEMOSTASIS; HUMAN; HYSTERECTOMY; MENOPAUSAL SYNDROME; OVARIECTOMY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM;

EID: 33845976021     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Notelovitz M. The clinical practice impact of the WHI: political vs. biologic correctness. Maturitas 2003; 44, 9 (3):29-34.
2. Salpeter SR, Walsh JME, Greyber E, et al. Mortality sssociated with HRT in younger and older women. J Gen Intern Med 2004; 19: 791-804.
3. Brooze Jr Gj. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood coagulation fibrinolysis 1995; 6 (Suppl): S7-13.
4. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: stucture, biology and involvement in disease, J Pathol 2006; 208 (3):327-9.
5. Bognacki J, Hemmelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1995; 6: 65-72.
6. Dahm A, van Hylckama Vlieg A, Bendz B, et al. Low levels of TFPI increase the risk of venous trombosis. Blood 2003; 101 (11): 4387-92.
7. Gottsater A, Rendell M, Hulthen UL, et al.: HRT in healthy postmenopausal women: a randomised placebo-controlled study of effects on coagulation and fibrinolytic factors. J Int Med 2001; 249: 237-46.
8. Modena MG, Sismondi P, Mueck AC, et al. New evidence regarding HRT is urgently required. Trandermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005; 52:1-10.
9. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362:428-32.
10. Peverill RE, Teede HJ, Smolich HH, et al. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII, Clinical Science 2001; 101: 93-9.
11. Bladbjerg EM, Skouby SO, Andersen LF, et al. Effects of different progestin regimens in HRT on blood coagulation factor VII and tissue factor pathway inhibitor, Human Reproduction 2002; 17 (12): 3235-41.
12. Bladbjerg EM, Madsen JS, Kristensen SR, et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomised controlled study. J Thromb Haemostas 2003; 1: 1208-14.
13. Hoibraaten E, Qvigstad E, Andersen TO, et al. The effects of HRT on hemostatisc variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trials. Thromb Haemostat 2001; 85: 775-81.
14. Hoke M, Kyrle PA, Minar E, et al. TFPI and the risk of recurrent venous tromboembolism. Throm Haemostat 2005; 94(4):787-90.
15. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal oestrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85(4): 619-25.
16. Martinez C, Masurto L, Zarate A, et al. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005; 50(1): 39-43.
17. Al-Farra HM, Al-Fahoum SK, Tabbaa MA. Effect of hormone replacement therapy on hemostatic variables in post-menopausal women. Saudi Med J. 2005; 26, 12: 1930-5.
18. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
19. Acs N, Vajo Z, Miklos Z, et al. The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta analysis of 46 studies. Gynecol Endocrinol 2002; 16: 335-46.
20. Writing Group for 3rd European Conference on Sex Steroids and Cardiovascular Diseases. The European Consensus Development Conference 2002: Sex Steroids and Cardiovascular Diseases. On the route to combined evidence from CC and HRT/ERT). Maturitas 2003; 44: 69-82.